Fraunhofer USA Center for Molecular Biotechnology Receives $60,000 From ProTecs

Reportedly, the Center’s new pilot production facility is nearing completion. Following the engineering test runs and facility validation to ensure FDA quality standards are met, production of product for clinical trials is expected to begin in 2010.

Vidadi Yusibov, executive director of Center, said: “The donation by ProTecs is important because it will aid the advancement of new vaccine manufacturing capabilities currently under development at Fraunhofer CMB. While CMB has developed a unique production platform for vaccine manufacturing, the service from ProTecs and their commitment to our project has been an important factor in helping us move forward with this new technology.”

Chris DiPaolo, founder and chief executive officer of ProTecs, said: “We are delighted to present this gift to Fraunhofer USA CMB to assist in the important work they are doing to bring safe, effective vaccines to global populations at reasonable costs. It was an honor to be selected as a valued partner on a project with such potential to positively impact global health.”